• Molecular Partners highlighted development of bispecific Radio-DARPins designed to engage multiple tumor targets, aiming to improve precision in radioligand therapy.
• It said multispecific formats could address tumor heterogeneity, building on its mono-targeting Radio-DARPin programs.
• Lead candidate MP0712, targeting DLL3, is in a multicenter US Phase 1/2a trial with Orano Med.
• Second candidate MP0726, targeting mesothelin, is expected to reach first human imaging this year.
• It expects to announce a third Radio-DARPin program in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief on July 15, 2026, and is solely responsible for the information contained therein.